Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs
Status:
Active, not recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to establish maximum tolerated doses/recommended phase 2 dose
(RP2D) of temozolomide (TMZ) and TAS-102 when these agents are used in combination and to
evaluate the safety profile of this drug combination.
Phase:
Phase 1
Details
Lead Sponsor:
University of Wisconsin, Madison
Collaborators:
National Cancer Institute (NCI) Taiho Pharmaceutical Co., Ltd.